Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4415—Pyridoxine, i.e. Vitamin B6
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7135—Compounds containing heavy metals
  • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
  • A61K33/08—Oxides; Hydroxides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/16—Otologicals

Definitions

• the invention relates to an agent for the treatment of tinnitus for oral administration, which contains blueberry extract, as well as antioxidants and micronutrients selected from magnesium oxide, vitamin B1, vitamin B2, vitamin B6, vitamin B 12, evening primrose oil and folic acid.
• blueberries as fresh fruits or (dry) extract
• circulatory disorders such as varices, hemorrhoids, diarrhea and a number of eye diseases such as cataracts, diabetogenic retinopathy, glaucoma, macular degeneration and night blindness as well as overuse of the eyes ( Computer) is widely used.
• Tinnitus is a dysfunction of the hearing system that can take on a variety of levels and structures, although there is no sound knowledge of the pathology of tinnitus.
• Tinnitus aurium (Latin for "the ringing of the ears"), or tinnitus for short, refers to a symptom in which the person perceives sounds that have no external source perceptible to other persons
• secondary symptoms such as sleep and concentration disorders, anxiety neurosis and depression, and often a normal lifestyle is limited or even impossible, and patients can become incapacitated for work or work.
• Patients suicidal As a cause of disease a multifactorial event is assumed. However, since there is no reliable knowledge about the pathophysiological basis of tinnitus, targeted rational drug therapy is not possible.
• the present invention accordingly provides a new, highly effective, purely natural drug or dietetic which is suitable for the prophylaxis and treatment of tinnitus / hearing loss.
• the medicaments according to the invention are natural, purely herbal formulations which are also well accepted and tolerated by patients who oppose allopathy.
• Blueberry extract according to the invention means a dry extract of the berries of Vaccinium myrtillus, i. the European blueberry, which is also called “Büberry” in Anglo-Saxon usage.
• a particularly preferred dry extract according to the invention is standardized to at least 25% anthocyanosides.
• a typical extract used according to the invention contains up to 4.5% water, up to 5% mineral parts (Sulfuric ashes), up to 5% free anthocyanidins and
• Such a Extract is commercially available eg as "BHberry Purified Dry Extract.”
• the dry extract can be prepared in a conventional manner from liquid drug extracts, for example by percolation, maceration, Soxhletmaschine, digestion in particular according to pharmacopoeia (eg Bonati A, J. Ethnopharmacol. 1991, April; 32 (1-3): 195-7)
• the blueberry extract used according to the invention can be prepared as shown briefly below.
• Fresh blueberries are squeezed to obtain a blueberry juice concentrate, which is then subjected to ultrafiltration and ethanol extraction or aqueous-alcoholic extraction.
• the resulting extract is concentrated in vacuo to a paste and dried to a powder, which is then ground to give the blueberry dry extract.
• a preferred formulation according to the invention contains per dosage unit, such as tablet or capsule:
• blueberry extract 50 to 500 mg of blueberry extract, 10 to 200 mg of magnesium (as magnesium oxide), 0.2 to 5 mg of vitamin B1, 0.2 to 5 mg of vitamin B2, 0.2 to 5 mg of vitamin B6, and 0.1 to 1 ⁇ g Vitamin B12.
• folic acid (0.01-10 mg) and evening primrose oil (10-100 mg).
• Vitamin B12 0.1 - 1 ⁇ g
• Vitamin B1 0.312 mg
• Vitamin B2 0.625 mg
• Vitamin B6 0.396 mg
• Vitamin B12 0.225 ⁇ g
• the dietetic agents or pharmaceutical agents according to the invention may also contain pharmaceutical formulation adjuvants such as fillers (carriers), e.g. Soybean oil or partially hydrogenated soybean oil, beeswax, butterfat and lecithin in soft gelatin capsules, disintegrants, binders, flow control agents, lubricants, emulsifiers, solvents or sorbents.
• carriers e.g. Soybean oil or partially hydrogenated soybean oil, beeswax, butterfat and lecithin in soft gelatin capsules
• disintegrants e.g. Soybean oil or partially hydrogenated soybean oil
• binders e.g. Soybean oil or partially hydrogenated soybean oil
• flow control agents e.g., lubricants, emulsifiers, solvents or sorbents.
• the dietetic agents or pharmaceutical agents according to the invention may be formulated in any dosage form suitable for oral administration by methods customary in the art, preferably solid dosage forms for oral administration such as tablets, hard gelatin capsules and soft gelatin capsules. Very particularly preferred are soft gelatin capsules. Oval soft capsules of sizes 2 to 20 minim and oblong soft capsules of sizes 6 to 22 minim, in particular oval soft capsules of size 10 minim, are preferred according to the invention. It is also particularly preferred in this case if the dosage form is present in special primary packaging means such as blister packs or blister packs, ie blistered. As can be seen from the results presented below, very significant treatment successes in the treatment of tinnitus could be achieved with the composition according to the invention, containing biaxin extract in combination with certain antioxidants and micronutrients.
• the patient has been suffering from ear noises for about 2-3 years. It usually perceives the ear noises on the left side as a noise. According to her information, she was therefore not at the doctor, she also took no medication in this regard. The sounds do not affect her daily life. Only before falling asleep, they were perceived as unpleasant.
• the patient started taking the composition according to the invention about 1 to 4 years ago (about mid-2005) and takes, partly irregularly, 2 capsules in the morning and 2 capsules in the evening. In case of migraine she adheres to the recommended intake described in the package insert.
• the patient has been suffering from tinnitus since 1993, who was diagnosed by an ear, nose and throat method and other methods by an ENT specialist. She perceives the tinnitus as whistling in the left ear. She does not take any medications in this regard, other therapeutic measures were not carried out with her.
• the patient is not restricted in her daily routine by the tinnitus, she indicates the strength of the sounds as "mediocre”. The patient takes for about 1/2 years regularly morning 3 Kapsein the inventive composition.
• the patient has had ear noises on both sides since 1997 and perceives them as whistles. She describes that the sounds occurred after a vertebral fracture and dental problems. A tinnitus diagnosis was not performed. The patient has performed no other therapeutic measures against tinnitus except a light music therapy. The ear noises were described as loud and thus disturbing. Due to the noise, the patient was partially restricted in her normal daily routine. She felt the sounds that affected her sleep, especially at night as very bad. The ear noises also made the patient appear more irritated to the family.
• the patient suffers from tinnitus as a result of a hearing loss since November 2005.
• the tinnitus was diagnosed by a naturopath.
• the patient perceived the ear noises as loud whistling and noise mostly on the right side.
• the noises did not cause any damage.
• the patient was extremely disturbed by the sounds at night, especially since she could not relax and could not fall asleep.
• the implementation of therapeutic measures such as acupuncture and massage and the use of tinnitus-matched globules were unsuccessful.
• the patient started taking the composition according to the invention in July 2006, since September 2006 she regularly takes 3 capsules in the morning and 3 capsules in the evening. From October 2006 she switched to the dose 2 capsules in the morning and 2 capsules in the evening.
• the ear noises which are z. existed for years, disappeared completely in 3 out of 4 patients. In one patient, the noise has improved significantly and the ear pressure is completely gone.
• Each of the patients has confirmed that the disappearance or amelioration of the ear noises is clearly due to the intake of the composition according to the invention.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Microbiology (AREA)
• Medical Informatics (AREA)
• Mycology (AREA)
• Alternative & Traditional Medicine (AREA)
• Biotechnology (AREA)
• Botany (AREA)
• Inorganic Chemistry (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicines Containing Plant Substances (AREA)
• Medicinal Preparation (AREA)
• Packages (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=38229816

Family Applications (1)

Country Status (9)

Families Citing this family (4)

Citations (1)

Family Cites Families (5)

• 2006
  • 2006-03-15 DE DE102006011922A patent/DE102006011922A1/de not_active Withdrawn
• 2007
  • 2007-03-15 US US12/282,691 patent/US20090220592A1/en not_active Abandoned
  • 2007-03-15 WO PCT/EP2007/002294 patent/WO2007104566A1/de not_active Ceased
  • 2007-03-15 CA CA002646528A patent/CA2646528A1/en not_active Abandoned
  • 2007-03-15 AU AU2007224668A patent/AU2007224668A1/en not_active Abandoned
  • 2007-03-15 EP EP07711962A patent/EP1993578A1/de not_active Ceased
  • 2007-03-15 JP JP2008558724A patent/JP2009529559A/ja active Pending
  • 2007-03-15 EA EA200801890A patent/EA013457B1/ru not_active IP Right Cessation
• 2008
  • 2008-09-14 IL IL194066A patent/IL194066A0/en unknown
• 2011
  • 2011-07-21 US US13/188,180 patent/US20110280972A1/en not_active Abandoned

Patent Citations (1)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events